## Antonio Jose Conde Moreno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7671480/publications.pdf

Version: 2024-02-01

44 papers 592 citations

759233 12 h-index 713466 21 g-index

45 all docs

45 docs citations

45 times ranked

927 citing authors

#	Article	IF	CITATIONS
1	Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). Journal of Clinical Oncology, 2016, 34, 597-602.	1.6	105
2	PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer, 2020, 20, 406.	2.6	64
3	Immune mechanisms mediating abscopal effects in radioimmunotherapy., 2019, 196, 195-203.		52
4	Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiation Oncology, 2014, 9, 258.	2.7	38
5	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clinical Medicine Insights: Oncology, 2018, 12, 117955491876336.	1.3	27
6	Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. Radiology and Oncology, 2016, 50, 337-340.	1.7	21
7	Precision Radiation Therapy for Metastatic Spinal Cord Compression: Final Results of the PRE-MODE Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 780-789.	0.8	18
8	Single-Fraction Versus 5-Fraction Radiation Therapy for Metastatic Epidural Spinal Cord Compression in Patients With Limited Survival Prognoses: Results of a Matched-Pair Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 93, 368-372.	0.8	17
9	Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study. Oncology Letters, 2017, 13, 4093-4100.	1.8	17
10	Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): a prospective multicenter study. BMC Cancer, 2019, 19, 1163.	2.6	14
11	Reverse koebnerization after radiotherapy in aÂwoman with a mastectomy for a breast carcinoma. Journal of the American Academy of Dermatology, 2006, 55, S90-S91.	1.2	13
12	Agreement in the assessment of metastatic spine disease using scoring systems. Radiotherapy and Oncology, 2015, 115, 135-140.	0.6	13
13	Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. Clinical and Translational Oncology, 2017, 19, 553-561.	2.4	12
14	A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. Radiation Oncology, 2015, 10, 173.	2.7	11
15	Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). Clinical and Translational Oncology, 2020, 22, 1378-1389.	2.4	11
16	Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment. Clinical and Translational Oncology, 2010, 12, 22-26.	2.4	10
17	1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups. Radiation Oncology, 2018, 13, 21.	2.7	10
18	Predictors of Outcomes and a Scoring System for Estimating Survival in Patients Treated With Radiotherapy for Metastatic Spinal Cord Compression From Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 322-329.	2.6	10

#	Article	IF	Citations
19	Uncertainties and CTV to PTV margins quantitative assessment using cone-beam CT technique in clinical application for prostate, and head and neck irradiation tumours. Clinical and Translational Oncology, 2011, 13, 819-825.	2.4	9
20	Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases. Clinical and Translational Oncology, 2016, 18, 342-351.	2.4	9
21	Patient-Reported Outcomes–Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy × 5 to 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2019, 105, 760-764.	0.8	9
22	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines, 2022, 10, 537.	3.2	9
23	100% peer review in radiation oncology: is it feasible?. Clinical and Translational Oncology, 2020, 22, 2341-2349.	2.4	8
24	The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy. Clinical and Translational Oncology, 2012, 14, 853-863.	2.4	7
25	A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression. BMC Cancer, 2016, 16, 292.	2.6	7
26	A Prognostic Instrument to Estimate the Survival of Elderly Patients Irradiated for Metastatic Epidural Spinal Cord Compression From Lung Cancer. Clinical Lung Cancer, 2016, 17, 279-284.	2.6	6
27	Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas. Reports of Practical Oncology and Radiotherapy, 2015, 20, 231-238.	0.6	5
28	High-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase 2 study. BMC Cancer, 2017, 17, 818.	2.6	5
29	SEORÂSBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis. Clinical and Translational Oncology, 2022, 24, 215-226.	2.4	5
30	Are there enough radiation oncologists to lead the new Spanish radiotherapy?. Clinical and Translational Oncology, 2019, 21, 1663-1672.	2.4	4
31	Recommended procedures and responsibilities for radiosurgery (SRS) and extracranial stereotactic body radiotherapy (SBRT): report of the SEOR in collaboration with the SEFM. Clinical and Translational Oncology, 2021, 23, 1281-1291.	2.4	4
32	Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group. Cancers, 2022, 14, 1130.	3.7	4
33	Results of a multicenter study investigating the potential impact of the overall treatment time on outcomes of radiation therapy alone with $5\tilde{A}$ —4 Gy for metastatic epidural spinal cord compression. Practical Radiation Oncology, 2017, 7, 137-144.	2.1	3
34	A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression. Radiation Oncology, 2018, 13, 257.	2.7	3
35	Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer. Reports of Practical Oncology and Radiotherapy, 2020, 25, 463-469.	0.6	3
36	Salvage I-125 brachytherapy for locally-recurrent prostate cancer after radiotherapy. Reports of Practical Oncology and Radiotherapy, 2020, 25, 754-759.	0.6	3

#	Article	IF	CITATIONS
37	Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain. Reports of Practical Oncology and Radiotherapy, 2020, 25, 405-411.	0.6	3
38	Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. Anticancer Research, 2018, 38, 1009-1015.	1.1	3
39	SEOR SBRT-SG survey on SRS/SBRT dose prescription criteria in Spain. Clinical and Translational Oncology, 2021, 23, 1794-1800.	2.4	2
40	Role of the overall treatment time of radiotherapy with $10 {\rm AA} - {\rm A3AG}$ for outcomes in patients with metastatic spinal cord compression. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 388-393.	1.8	1
41	To the editor, response letter. Clinical and Translational Oncology, 2021, 23, 1729-1730.	2.4	1
42	The Contribution of the Cone Beam CT (CBCT) to the Reduction in Toxicity of Prostate Cancer Treatment with External 3D Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, S445.	0.8	0
43	Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated with with abiraterone acetate or enzalutamide. Annals of Oncology, 2018, 29, viii285.	1.2	0
44	Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer Journal of Clinical Oncology, 2019, 37, e16530-e16530.	1.6	0